Susquehanna International Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Susquehanna International Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$61.1K	Sell	12,600 -32,700	-72%	-$131K	﹤0.01%	12756
2026 Q1	$106K	Buy	+45,300	New	+$117K	﹤0.01%	12308
2025 Q4	–	Sell	-10,400	Closed	-$15.7K	–	13814
2025 Q3	$15.7K	Buy	+10,400	New	+$15.6K	﹤0.01%	12073
2025 Q2	–	Sell	-30,900	Closed	-$49.1K	–	13869
2025 Q1	$49.1K	Buy	30,900 +16,100	+109%	+$34.7K	﹤0.01%	11872
2024 Q4	$44.8K	Sell	14,800 -18,200	-55%	-$59.6K	﹤0.01%	11722
2024 Q3	$121K	Buy	+33,000	New	+$120K	﹤0.01%	10912
2024 Q1	–	Sell	-30,200	Closed	-$458K	–	13530
2023 Q4	$458K	Buy	30,200 +12,800	+74%	+$187K	﹤0.01%	8893
2023 Q3	$349K	Sell	17,400 -18,500	-52%	-$470K	﹤0.01%	9030
2023 Q2	$1.01M	Buy	+35,900	New	+$861K	﹤0.01%	6647
2021 Q3	–	Sell	-12,500	Closed	-$665K	–	13717
2021 Q2	$665K	Buy	+12,500	New	+$669K	﹤0.01%	8871

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Susquehanna International Group's ZNTL Position: Q2 2026 in Review

Susquehanna International Group reduced its Zentalis Pharmaceuticals (ZNTL) stake by 62% in Q2 2026, selling an estimated $1.42M and leaving 215,113 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #8096.

Susquehanna International Group first reported a position in ZNTL in Q4 2020 and has held it in 23 quarters since. The position peaked at $3.22M in Q3 2021. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

Susquehanna International Group held 215,113 shares of Zentalis Pharmaceuticals worth $1.04M as of Q2 2026.
Susquehanna International Group sold 356,144 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $1.42M.
Zentalis Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #8096 holding.
Susquehanna International Group first reported a position in Zentalis Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
Susquehanna International Group's Zentalis Pharmaceuticals position peaked at $3.22M in Q3 2021.
114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.